MRI and targeted biopsy essential tools for an accurate diagnosis and treatment decision making in prostate cancer
Author
dc.contributor.author
Samtani, Suraj
Author
dc.contributor.author
Burotto, Mauricio
Author
dc.contributor.author
Román, Juan Carlos
Author
dc.contributor.author
Cortés Herrera, Daniela
Author
dc.contributor.author
Walton Díaz, Annerleim Nylsello
Admission date
dc.date.accessioned
2022-01-07T15:40:00Z
Available date
dc.date.available
2022-01-07T15:40:00Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Diagnostics 2021, 11, 1551
es_ES
Identifier
dc.identifier.other
10.3390/diagnostics11091551
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/183498
Abstract
dc.description.abstract
Prostate cancer (PCa) is one of the most frequent causes of cancer death worldwide.
Historically, diagnosis was based on physical examination, transrectal (TRUS) images, and TRUS
biopsy resulting in overdiagnosis and overtreatment. Recently magnetic resonance imaging (MRI) has
been identified as an evolving tool in terms of diagnosis, staging, treatment decision, and follow-up.
In this review we provide the key studies and concepts of MRI as a promising tool in the diagnosis
and management of prostate cancer in the general population and in challenging scenarios, such
as anteriorly located lesions, enlarged prostates determining extracapsular extension and seminal
vesicle invasion, and prior negative biopsy and the future role of MRI in association with artificial
intelligence (AI).
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
MDPI
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States